期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同时间新辅助内分泌疗法对局部晚期前列腺癌疗效的影响

Effect of different time neoadjuvant hormornal therapy for locally advanced prostate cancer
原文传递
导出
摘要 目的 探讨局部晚期前列腺癌联合治疗中新辅助内分泌疗法（ NHT）的理想方案.方法 诊断明确的局部晚期（T3-4N0M0）前列腺癌患者60例,均采用NHT治疗方案.治疗前随机分为3组,每组20例,各组行不同时间NHT,A组：2周NHT,B组：3个月NHT,C组：6个月NHT.结果 A、B、C组患者NHT后前列腺特异抗原（PSA）中位值分别为24.88（ 6.62～55.86）、0.20（0.05～12.07）和0.07（ 0.01～2.01） ng/ml,与治疗前比较差异均有统计学意义（均P=0.00）,组间比较差异有统计学意义（均P=0.00）.A、B、C组行NHT后前列腺体积分别为（49.50±14.19）、（47.35±17.99）和（36.15±7.17）ml,B、C两组治疗前后前列腺体积比较差异有统计学意义（P=0.04、0.00）,治疗后A组与C组、B组与C组比较差异有统计学意义（P=0.00、0.01）.A、B和C组治疗后最大尿流率（Qmax）平均值分别为（ 8.75±2.15）、（11.70±2.81）和（14.45±2.61）ml/s,B组和C组治疗前后比较差异有统计学意义（均P=0.00）,治疗后各组间比较差异有统计学意义（均P=0.00）.结论 NHT治疗时间至少应达到3个月,能够达到降低PSA。 Objective To investigate ideal solution of neoadjuvant hormomal therapy （NHT） for locally advanced prostate cancer.Methods 60 patients diagnosed with locally advanced （T3-4N0M0） prostate cancer were treated with NHT.They were randomly divided into 3 groups of 20 cases.A group：NHT 2 weeks,B group：NHT 3 months,C group：NHT 6 months.Results The median PSA of A,B and C group after NHT were 24.88 （6.62-55.86）,0.20 （0.05-12.07） and 0.07 （0.01-2.01） ng/ml,respectively.There was statistically significance compared with those in untreatment （ all P =0.00）.There was statistically significant （P =0.00）among groups.The prostate volume of A,B and C group were （49.50＋14.19）,（47.35±17.99） and （36.15±7.17）ml,respectively.There was statistically significance in the B and C group compared with that in untreatment （P =0.04,0.00）.There was statistically significant between A and C group and between B and C group （P =0.00,0.01）.The Qmax of A,B and C group were （8.75±2.15）,（11.7±2.81） and （14.45±2.61） ml/s,respectively.There was statistically significance in the B and C group compared with untreatment （both P =0.00）.There was statistically significance among groups （all P =0.00）.Conclusion The NHT time should last at least 3 months in order to reduce PSA and prostate volume and to increase the Qmax
作者 侯瑞鹏 李健 王凤玮 张志华 尉皓 唐涛 张华
机构地区 天津市人民医院泌尿外科 天津市人民医院肿瘤科 天津市人民医院病理科 天津市人民医院超声科
出处 《肿瘤研究与临床》 CAS 2011年第10期684-686,共3页 Cancer Research and Clinic
基金 天津市卫生局科技基金（09KZ59）
关键词 前列腺肿瘤 前列腺特异抗原 局部晚期 新辅助内分泌疗法 Prostatic neoplasms Prostate-specific antigen Locally advanced Neoadjuvant hormomal therapy
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Olapade-Olaopa EO,Obamuyide HA,Yisa GT.Management of advanced prostate cancer in Africa.Can J Urol,2008,15:3890-3898.
  • 2孙颖浩.我国前列腺癌的研究现状[J].中华泌尿外科杂志,2004,25(2):77-80. 被引量：355
  • 3姚欣,李文录,庞青松,贾炜莹,马腾骧.睾丸切除术联合放疗治疗C期前列腺癌的临床观察[J].肿瘤研究与临床,2000,12(6):408-410. 被引量：2
  • 4刘喜波,孟春琴.Ki-67和CK34βE12在前列腺癌鉴别诊断中的应用[J].肿瘤研究与临床,2005,17(3):187-188. 被引量：5
  • 5钟秋子,李高峰.前列腺特异性抗原在前列腺癌治疗中的应用进展[J].中华放射肿瘤学杂志,2010,19(2):176-178. 被引量：3
  • 6Tunn UW,Acar O,Goldschmidt AJ.Effects of androgen deprivation prior to radical prostatectomy in 375 patients.Urol Int,1996,56:6-12.
  • 7Chen M,Hricak H,Kalbhen CL,et al.Hormonal ablation of prostatic cancer:effects on prostate morphology,tumor detection,and staging by endorectal coil MR imaging.Am J Roentgenol,1996,166:1157-1163.
  • 8Gleave ME,Goldenberg SL,Jones EC,et al.Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.J Urol,1996,155:213-219.
  • 9Tunn UW.Neo-adjuvanthormomal therapy of prostate cancer.Urol Res,1997,25 Suppl 2:S57-62.
  • 10Hsu CY,Joniau S,Roskams T,et al.Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy.BJU Int,2007,99:311-314.

二级参考文献40

  • 1刘峰,王俊杰.放射性^(103)Pd粒子植入治疗前列腺癌[J].中国微创外科杂志,2008,8(2):183-185. 被引量：3
  • 2Han M,Partin AW,Pound CR,et al.Long-term biochemical disease-free and cancer-specific survival following anatomic radical retrepubic prostatectomy.The 15-year Johns Hopkins experience.Urol Clin North Am,2001,28:555-565.
  • 3Amling CL,Bergstralh El,Blute ML,et al.Defining prostate specific antigen progression after radical prostatectomy:what is the most appropriate cut point? J Urol,2001,165:1146-1151.
  • 4Freedland SJ,Surfer ME,Dorey F,et al.Defining the ideal cutpoint for determining psa recurrence after radical prostatectomy.Urology,2003,61:365-369.
  • 5Bolla M,van Poppel H,Collette L,et al.Postoperative radiotherapy after radical prostatectomy:a randomised controlled trial (EORTC trial 22911).Lancet,2005,366:572-578.
  • 6Swanson GP,Hussey MA,Tangen CM,et al.Predominant treatment failure in postprostatectomy patients is local:analysis of patterns of treatment failure in SWOG 8794.J Clin Oncol,2007,25:5671-5672.
  • 7Trock B J,Han M,Freedland SJ,et al.Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.JAMA,2008,299:2760-2769.
  • 8Kupelian PA,Katcher J,Levin HS,et al.Stage T(1-2) prostate cancer:a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy,Int J Radiat Oncol Biol Phys,1997,37:1043-1052.
  • 9Pound CR,Partin AW,Epstein JI,et al.Prostate-specific antigen after anatomic radical retropubic prostatectomy.Patterns of recurrence and cancer control.Urol Clin North Am,1997,24:395-406.
  • 10Van der Kwast TH,Bolla M,Van Poppel H,et al.Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy:EORTC 22911.J Clin Oncol,2007,25:4178-4186.

共引文献361

肿瘤研究与临床
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部